카페시타빈 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the capecitabine market size is expected to grow from USD 494.28 million in 2025 to USD 523.98 million in 2026 and is forecast to reach USD 701.35 million by 2031 at 6.01% CAGR over 2026-2031.

This report is Segmented by Indication (Breast Cancer, Colorectal Cancer, Gastric Cancer, and More), Distribution Channel (Hospitals, Retail & Online Pharmacies, and More), Dosage Strength (150 Mg Tablets and 500 Mg Tablets), Formulation (Branded and Generic), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Capecitabine Market Trends and Insights

Escalating Global Cancer Incidence

The World Health Organization reports that worldwide cancer cases will reach 35 million by 2050, a 77% jump over current levels. Colorectal and breast cancers-two leading uses of capecitabine-feature prominently in this uptrend, widening the treatment pool for oral fluoropyrimidines. Low- and middle-income countries, where 39% of facilities still lack comprehensive oncology services, view oral regimens as practical substitutes for infusion therapy thanks to simpler logistics and lower infrastructure demands. Ageing demographics in industrialised nations also favour less-toxic outpatient modalities that permit quality-of-life preservation. These converging epidemiological factors steadily support long-term capecitabine market growth.

Intensifying Government Oncology Initiatives

Government spending continues to elevate oncology on public-health agendas. In the United States, the Congressionally Directed Medical Research Program allocated USD 650 million to cancer research in 2025, funding both discovery and access schemes. Similar commitments in Europe underpin reshoring of critical APIs to safeguard supply. Subsidies for oral chemotherapy, coupled with tele-oncology expansion, expand home-based treatment footprints in both developed and emerging markets. These policies create a supportive environment for the capecitabine market by boosting reimbursement certainty and promoting distribution channels beyond acute-care settings.

High Total Treatment Cost of Multi-Cycle Capecitabine

Even after generic entry, cumulative therapy costs over several months can burden uninsured patients and public payers. Coverage disparities between oral and infusion drugs persist in many systems, limiting uptake despite documented clinical parity. Recent US legislation capping Medicare Part D out-of-pocket spending may shift that balance, yet the mid-term outlook remains sensitive to national reimbursement reforms.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Generic Penetration Post-Xeloda Patent Expiry
2. Patient Preference for Oral & Home-Based Chemotherapy
3. Hand-Foot Syndrome Limiting Adherence & Dosage

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Colorectal cancer generated 45.02% of capecitabine market size in 2025, sustained by guideline-endorsed CAPOX protocols across adjuvant and metastatic settings. Clinical parity with continuous 5-fluorouracil infusions and superior convenience underpin durable demand. Pancreatic malignancies, though currently smaller in absolute terms, are set to log a 7.22% CAGR through 2031 as evidence mounts for capecitabine's benefit in combination regimens such as gemcitabine-capecitabine following surgical resection.

Growing interest in immunotherapy-augmented strategies positions capecitabine for niche expansion beyond first-line colorectal applications. Investigator-initiated studies are also exploring esophageal and biliary cancers, signalling incremental broadening of the capecitabine market. Regulatory approvals in these additional disease states would reinforce its multi-indication footprint.

Hospitals captured 52.90% of capecitabine market share in 2025 thanks to oncology clinics embedded in tertiary centres. Physician-pharmacy integration allows on-site dispensing and close adherence monitoring, reinforcing institutional dominance. Nevertheless, retail and online pharmacies are set to rise 8.33% annually as health-systems pursue omni-channel strategies that improve refill convenience and geographic reach.

Medically integrated dispensing models inside health-systems have been shown to offer lower out-of-pocket prices on high-cost oral oncology drugs compared with external stores. Specialty pharmacies further bolster patient support through counselling and financing assistance. Consequently, channel diversification provides redundancy that strengthens overall capecitabine market resilience during localised shortages.

Complete Report Scope:

• By Indication
  • Colorectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Other Cancers
• By Distribution Channel
  • Hospitals
  • Oncology Clinics / Clinical Laboratories
  • Retail & Online Pharmacies
  • Others
• By Dosage Strength
  • 150 mg Tablets
  • 500 mg Tablets
• By Formulation
  • Branded
  • Generic
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America's entrenched oncology infrastructure, complete with medically integrated dispensing, ensures dependable access and reimbursement for capecitabine. The region's high prevalence of colorectal cancer keeps demand stable, while expanding use of metronomic dosing in elderly pancreatic-cancer patients outlines incremental upside. Manufacturers hedging against domestic shortages are partnering with contract development and manufacturing organisations to maintain buffer inventory.

Asia-Pacific's momentum stems from rapid improvements in diagnostic capacity and public awareness. Large-scale screening campaigns are identifying colorectal and gastric cancers earlier, bringing patients into treatment corridors where oral regimens offer logistical convenience. Government grants that offset capital costs for local API plants reduce vulnerability to external supply shocks, fostering sustainable growth in the capecitabine market.

Europe's universal health systems facilitate equitable access, yet stringent pharmacovigilance standards demand upfront genotyping and therapeutic-drug-monitoring, slightly lengthening the treatment pathway. Regional manufacturers are investing in process intensification and green-chemistry initiatives to align with European Union sustainability goals, actions that may translate into competitive export positions over the long term.

1. CHEPLAPHARM Arzneimittel GmbH
2. Teva Pharmaceutical Industries
3. Viatris (Mylan)
4. Hikma Pharmaceuticals
5. Cipla
6. Dr Reddy's Laboratories
7. Fresenius
8. Intas Pharmaceuticals
9. Sun Pharmaceuticals Industries
10. Armas Pharmaceuticals
11. Accord Healthcare
12. Aurobindo Pharma
13. Apotex
14. Lupin
15. Sandoz Group
16. Glenmark Pharma
17. Torrent Pharmaceuticals
18. Zydus Lifesciences
19. Strides Pharma
20. Polpharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Global Cancer Incidence
  • 4.2.2 Intensifying Government Oncology Initiatives
  • 4.2.3 Rapid Generic Penetration Post-Xeloda Patent Expiry
  • 4.2.4 Patient Preference For Oral & Home-Based Chemotherapy
  • 4.2.5 Uptake In Immunotherapy Combination Regimens (MSI-H)
  • 4.2.6 Emerging Metronomic Dosing Adoption In LMIC Palliative Care
• 4.3 Market Restraints
  • 4.3.1 High Total Treatment Cost Of Multi-Cycle Capecitabine
  • 4.3.2 Hand-Foot Syndrome Limiting Adherence & Dosage
  • 4.3.3 API Supply Shortages & Manufacturing Disruptions
  • 4.3.4 Mandatory DPD-Deficiency Genetic Testing Delays
• 4.4 Supply-Chain Analysis
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Indication
  • 5.1.1 Colorectal Cancer
  • 5.1.2 Breast Cancer
  • 5.1.3 Gastric Cancer
  • 5.1.4 Pancreatic Cancer
  • 5.1.5 Other Cancers
• 5.2 By Distribution Channel
  • 5.2.1 Hospitals
  • 5.2.2 Oncology Clinics / Clinical Laboratories
  • 5.2.3 Retail & Online Pharmacies
  • 5.2.4 Others
• 5.3 By Dosage Strength
  • 5.3.1 150 mg Tablets
  • 5.3.2 500 mg Tablets
• 5.4 By Formulation
  • 5.4.1 Branded
  • 5.4.2 Generic
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 CHEPLAPHARM Arzneimittel GmbH
  • 6.3.2 Teva Pharmaceuticals
  • 6.3.3 Viatris (Mylan)
  • 6.3.4 Hikma Pharmaceuticals
  • 6.3.5 Cipla Ltd
  • 6.3.6 Dr Reddy's Laboratories
  • 6.3.7 Fresenius Kabi
  • 6.3.8 Intas Pharmaceuticals
  • 6.3.9 Sun Pharma
  • 6.3.10 Armas Pharmaceuticals
  • 6.3.11 Accord Healthcare
  • 6.3.12 Aurobindo Pharma
  • 6.3.13 Apotex
  • 6.3.14 Lupin Ltd
  • 6.3.15 Sandoz AG
  • 6.3.16 Glenmark Pharma
  • 6.3.17 Torrent Pharma
  • 6.3.18 Zydus Lifesciences
  • 6.3.19 Strides Pharma
  • 6.3.20 Polpharma

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment